Orthofix Q2 Sales Rise 5%, Raises Full-Year Guidance; CMS Reimbursement Restored
OFIX sits 51% above its 52-week low of $8.85.
Summary
Orthofix Medical reported Q2 2026 net sales of $210.9M, up 5% on a pro forma constant currency basis, and raised full-year 2026 guidance. CMS restored Medicare reimbursement for bone growth stimulators, removing a temporary headwind.
Key Events · Earnings and Guidance · OFIX
-
Q2 Revenue Beats, Guidance Raised
Net sales of $210.9M grew 5% pro forma constant currency. Full-year 2026 guidance raised for both revenue and adjusted EBITDA, reversing the May guidance cut.
-
CMS Reimbursement Restored
On July 1, 2026, CMS withdrew May 2026 billing changes for bone growth stimulators, restoring prior reimbursement rates. This removes a temporary pricing headwind for the Therapeutic Solutions segment.
-
Gross Margin Expands to 71%
Gross margin improved 230 bps year-over-year to 71.0%, driven by lapping M6 product line discontinuation charges and higher sales volumes.
-
Cash Burn Continues
Operating cash flow was negative $23.8M in H1 2026, worse than the $6.8M used in H1 2025, driven by working capital build and litigation settlement payments. Cash balance stands at $103.8M.
Analysis · OFIX · Industrial Applications And Services
A solid quarter for Orthofix, with 5% pro forma constant currency revenue growth, prompted an upward revision to the full-year outlook for both revenue and adjusted EBITDA. Gross margin expanded to 71%, helped by the absence of last year's heavy M6-related impairment charges. The July 1 CMS reversal of bone growth stimulator reimbursement cuts removes a key overhang that had pressured Therapeutic Solutions pricing in Q2. Cash burn remains a concern — operations used $23.8M in the first half — but the company holds $103.8M in cash and has access to additional credit. The raised guidance and regulatory tailwind are the main stories here.
How filings like this one have moved
In the 30 days to Sep 19, 2026, 34.7% of the 1096 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OFIX was trading at $13.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $493.1M. The 52-week trading range was $8.85 to $16.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.